NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Eribulin for treating locally advanced or metastatic breast cancer after chemotherapy [ID964]

Draft scope

Remit
To appraise the clinical and cost effectiveness of eribulin within its marketing authorisation of the treatment for people with breast cancer who have received one or more chemotherapy regimens for locally advanced or metastatic disease.

Background
Breast cancer arises from the tissues of the ducts or lobules of the breast. ‘Locally advanced’ cancer describes tumours that are larger than 5 cm in size, and may have grown into the skin or muscle of the chest or nearby lymph nodes. Metastatic breast cancer describes disease that has spread to another part of the body, such as the bones, liver, or lungs.

Over 44,800 people were diagnosed with breast cancer in England in 2013, and there were approximately 9800 deaths from breast cancer in 2012\(^1,2\). The 5-year survival rate for people with metastatic breast cancer in England is 15%.\(^3\) Approximately 16% of people with invasive breast cancers have locally advanced or metastatic disease when they are diagnosed\(^4\), and around 35% of people with early or locally advanced disease will progress to metastatic breast cancer\(^5,6\).

Current treatments for locally advanced or metastatic breast cancer aim to relieve symptoms, prolong survival and maintain a good quality of life with minimal adverse events. Treatment may depend on whether the cancer cells have particular receptors (oestrogen receptor or HER2), the extent of the disease and previous treatments; options include endocrine therapies, biological therapies and chemotherapy. For advanced breast cancer NICE clinical guideline 81 recommends endocrine therapy.

For people having chemotherapy for advanced breast cancer, NICE clinical guideline 81 (CG81) recommends anthracycline-based regimens as the initial treatment, followed by sequential lines of treatment with docetaxel first line followed by capecitabine and vinorelbine as second or third line. Gemcitabine monotherapy is also used in clinical practice in the UK. Patients for whom anthracyclines are not suitable (because of contraindication or progression on prior anthracycline treatment) are offered sequential treatment with systemic chemotherapy.
The technology
Eribulin (Halaven, Eisai) is a synthetic analogue of halichondrin B, which inhibits tubulin polymerisation. The destabilisation of tubulin polymers disrupts the assembly and formation of microtubules, which in turn arrests cancer cell division. It is administered intravenously.

Eribulin is indicated for ‘the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting’ unless these treatments were not suitable.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Eribulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease (anthracycline and a taxane, unless these treatments were not suitable).</td>
</tr>
</tbody>
</table>
| Comparators  | • vinorelbine  
• capecitabine  
• gemcitabine |
| Outcomes     | The outcome measures to be considered include:  
• overall survival  
• progression free survival  
• response rate  
• adverse effects of treatment  
• health-related quality of life. |
| Economic analysis | The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.  
The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.  
Costs will be considered from an NHS and Personal Social Services perspective.  
The availability of any patient access schemes for the intervention or comparator technologies will be taken into account. |
Other considerations

Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.

<table>
<thead>
<tr>
<th>Related NICE recommendations and NICE Pathways</th>
<th>Related Technology Appraisals:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Related Technology Appraisals:</strong></td>
<td>Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (2013) NICE technology appraisal guidance TA295. Review ongoing, publication date TBC</td>
</tr>
<tr>
<td></td>
<td>Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (2015) NICE technology appraisal guidance 371. Review date December 2018</td>
</tr>
<tr>
<td></td>
<td>Fulvestrant for the treatment of locally advanced or metastatic breast cancer (2011) NICE technology appraisal guidance 239. Review date Nov 2014. Review decision, static list</td>
</tr>
</tbody>
</table>

Suspended appraisals

<table>
<thead>
<tr>
<th><strong>Suspended appraisals</strong></th>
<th><strong>Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer)</strong> NICE technology appraisal guidance. Suspended.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Trastuzumab as monotherapy and in combination with a taxane for the treatment of metastatic breast cancer (to include a review of TA34)</strong>. NICE technology appraisals guidance. Suspended.</td>
</tr>
</tbody>
</table>

**Proposed Technology Appraisals:**

<table>
<thead>
<tr>
<th><strong>Proposed Technology Appraisals:</strong></th>
<th>Palbociclib for treating metastatic, hormone receptor-</th>
</tr>
</thead>
</table>
positive, HER2-negative breast cancer. Proposed NICE technology appraisal [ID915]. Publication date to be confirmed.

Etirinotecan pegol (after chemotherapy). Proposed NICE technology appraisal [ID881]. Publication date to be confirmed.

### Related Guidelines:

**Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer** (2013). NICE guideline CG164

Review date: December 2015


### Related Quality Standards:


### Related NICE Pathways:

**Advanced breast cancer** (2015) NICE pathway

**Familial breast cancer** (2015) NICE pathway

**Early and locally advanced breast cancer** (2014) NICE pathway

### Related National Policy

NHS England, Manual for prescribed specialised services 2013/14: Chapter 105. Specialist Cancer services (adults)


Questions for consultation

Have all relevant comparators for eribulin been included in the scope? Which treatments are considered to be established clinical practice in the NHS for locally advanced or metastatic breast cancer which has been treated with one or more chemotherapy regimens?

Are the outcomes listed appropriate?

Are there any subgroups of people in whom eribulin is expected to be more clinically effective and cost effective or other groups that should be examined separately?

Where do you consider eribulin will fit into the existing NICE pathways, Early and locally advanced breast cancer (2014) and Advanced breast cancer (2015)?

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the proposed remit and scope may need changing in order to meet these aims. In particular, please tell us if the proposed remit and scope:

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which eribulin is licensed;

- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;

- could have any adverse impact on people with a particular disability or disabilities.

Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.

Do you consider eribulin to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a ‘step-change’ in the management of the condition)?
Do you consider that the use of eribulin can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation?

Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.

References